VX 478
Showing 1 - 25 of 176
HIV Trial in United States (Indinavir sulfate, Amprenavir, Nevirapine)
Completed
- HIV Infections
- Indinavir sulfate
- +5 more
-
Los Angeles, California
- +11 more
Oct 28, 2021
Breast Cancer, Gynecologic Cancer, HNSCC Trial in Boston (STX-478, Fulvestrant)
Recruiting
- Breast Cancer
- +3 more
-
Boston, MassachusettsMassachusetts General Hospital
Mar 13, 2023
HIV Trial in United States (Indinavir sulfate, Ritonavir, Amprenavir)
Completed
- HIV Infections
- Indinavir sulfate
- +5 more
-
Palo Alto, California
- +7 more
Oct 28, 2021
Cystic Fibrosis Trial in Worldwide (VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA)
Active, not recruiting
- Cystic Fibrosis
- VX-121/TEZ/D-IVA
- +5 more
-
Birmingham, Alabama
- +169 more
Dec 22, 2022
Alpha-1 Antitrypsin Deficiency Trial (VX-668, Placebo)
Not yet recruiting
- Alpha-1 Antitrypsin Deficiency
- VX-668
- Placebo
- (no location specified)
Feb 3, 2023
Focal Segmental Glomerulosclerosis (FSGS) Trial (VX-147)
Not yet recruiting
- Focal Segmental Glomerulosclerosis (FSGS)
- (no location specified)
Jul 13, 2023
HIV Trial in Puerto Rico, United States (Indinavir sulfate, Abacavir sulfate, Amprenavir)
Completed
- HIV Infections
- Indinavir sulfate
- +7 more
-
Los Angeles, California
- +44 more
Oct 27, 2021